China-Singapore Suzhou Valuation Multiples

Discover China-Singapore Suzhou's revenue and EBITDA valuation multiples and investment history, alongside public comparables like GIMV, Kinnevik, Georgia Capital, Antin Infrastructure Partners and more.

China-Singapore Suzhou Overview

About China-Singapore Suzhou

China-Singapore Suzhou Industrial Park Development Group Co Ltd is engaged in development and construction for the Suzhou Industrial Park. The company through its subsidiaries, focuses on the construction, investment promotion and operation of the district's parks. It has implemented park development and operation projects in Anhui, Zhejiang, Ningxia and other places.


Founded

2008

HQ

China

Employees

N/A

Sectors

Financials (LTM)

Revenue: $472M
EBITDA: $284M

EV

$3.5B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

China-Singapore Suzhou Financials

China-Singapore Suzhou reported last 12-month revenue of $472M and EBITDA of $284M.

In the same LTM period, China-Singapore Suzhou generated $209M in gross profit, $284M in EBITDA, and $155M in net income.


China-Singapore Suzhou P&L

In the most recent fiscal year, China-Singapore Suzhou reported revenue of $479M and EBITDA of $331M.

China-Singapore Suzhou is profitable as of last fiscal year, with gross margin of 44%, EBITDA margin of 69%, and net margin of 33%.

See analyst estimates for China-Singapore Suzhou
LTMLast FY2025202620272028
Revenue$472M$479M$479M
Gross Profit$209M$212M$212M
Gross Margin44%44%44%
EBITDA$284M$331M$331M
EBITDA Margin60%69%69%
EBIT Margin47%33%33%
Net Profit$155M$157M$157M
Net Margin33%33%33%
Net Debt-$899M-

Financial data powered by Morningstar, Inc.

China-Singapore Suzhou Stock Performance

China-Singapore Suzhou has current market cap of $1.9B, and enterprise value of $3.5B.


China-Singapore Suzhou's stock price is $1.28.

China-Singapore Suzhou has an EPS (earnings per share) of $0.10.

See more trading valuation data for China-Singapore Suzhou
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$3.5B$1.9B0.5%---$0.10

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

China-Singapore Suzhou Valuation Multiples

China-Singapore Suzhou trades at 7.4x EV/Revenue multiple, and 12.3x EV/EBITDA.

See NTM and 2027E valuation multiples for China-Singapore Suzhou

China-Singapore Suzhou Financial Valuation Multiples

As of September 5, 2026, China-Singapore Suzhou has market cap of $1.9B and EV of $3.5B.

China-Singapore Suzhou has a P/E ratio of 12.4x.

LTMLast FY2025202620272028
EV/Revenue7.4x7.3x7.3x
EV/EBITDA12.3x10.6x10.6x
EV/EBIT15.8x22.1x22.1x
EV/Gross Profit16.8x16.5x16.5x
P/E12.4x12.2x12.2x
EV/FCF-28.4x28.4x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified China-Singapore Suzhou Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

China-Singapore Suzhou Margins & Growth Rates

China-Singapore Suzhou grew revenue by 12% but EBITDA decreased by 6% in the last fiscal year.

In the most recent fiscal year, China-Singapore Suzhou reported gross margin of 44%, EBITDA margin of 69%, and net margin of 33%.

See estimated margins and future growth rates for China-Singapore Suzhou

China-Singapore Suzhou Margins

Last FY20252026202720282029
Gross Margin44%44%44%
EBITDA Margin69%69%58%
EBIT Margin33%33%42%
Net Margin33%33%30%
FCF Margin26%26%-

China-Singapore Suzhou Growth Rates

FY+1/FY25/2626/2727/2828/29
Revenue Growth12%12%
Gross Profit Growth12%12%
EBITDA Growth(6%)(6%)
EBIT Growth41%41%
Net Profit Growth3%3%

Data powered by FactSet, Inc. and Morningstar, Inc.

China-Singapore Suzhou Operational KPIs

China-Singapore Suzhou's Rule of 40 is 70% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

China-Singapore Suzhou's Rule of X is 88% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for China-Singapore Suzhou
LTMLast FY2025202620272028
Rule of 4077%70%-
Bessemer Rule of X103%88%-
S&M Expenses to Revenue0%0%0%
G&A Expenses to Revenue8%1%1%
R&D Expenses to Revenue0%0%0%
Opex to Revenue-11%11%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

China-Singapore Suzhou Competitors

China-Singapore Suzhou competitors include GIMV, Kinnevik, Georgia Capital, Antin Infrastructure Partners, Rocket Internet, Molten Ventures, Bure Equity, China Everbright, Fairfax India Holdings and Ratos.

Most China-Singapore Suzhou public comparables operate across PE & VC.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
GIMV6.0x---
Kinnevik(5.1x)-(4.0x)(15.0x)
Georgia Capital2.5x---
Antin Infrastructure Partners4.2x4.2x7.5x7.9x
Rocket Internet15.4x-1.7x-
Molten Ventures8.9x7.4x10.0x9.2x
Bure Equity83.9x-(4.8x)-
China Everbright23.0x10.2x--

This data is available for Pro users. Sign up to see all China-Singapore Suzhou competitors and their valuation data.

Start Free Trial

Investments by China-Singapore Suzhou

China-Singapore Suzhou has invested in 6 companies to date.

Latest investment by China-Singapore Suzhou was on August 31st 2026. China-Singapore Suzhou invested in Miwei Technology in their Series A round.

See VC round multiples

Latest Investments by China-Singapore Suzhou

Miwei Technology
Guoshun Laser
Xiangzhi Technology
Ractigen Therapeutics
Description
Miwei Technology is a China-based developer of service-oriented intelligent computing systems, encompassing operating systems, edge computing, and cloud solutions.
Guoshun Laser is a Chinese developer of high-power ultrafast micro-nano structure fiber lasers. Guoshun Laser produces advanced laser systems for industrial and scientific applications.
Xiangzhi Technology is a developer of optoelectronic sensors including lidar and optical gyroscopes for multi-modal applications.
Ractigen Therapeutics is a San Francisco-headquartered biotech firm advancing RNA activation therapies to reactivate silenced genes in oncology and neurodegeneration. Its lead candidates target EZH2 and p21 genes using synthetic saRNAs delivered via lipid nanoparticles. Founded in 2016 from UCSF research, Ractigen advances clinical trials for liver cancer and holds patents on RNAa platforms licensed from the university. The pipeline includes programs for Alzheimer's partnered with academic labs.
HQ CountryChinaChinaChinaChina
HQ City
-
Suzhou
-
Nantong
Deal Date31 Aug 202616 Mar 202624 Nov 202527 Jan 2022
RoundSeries ASeries ASeedSeries A
Raisedundisclosedundisclosedundisclosed$30M
InvestorsMatrix Partners China; Tsinghua Holdings Capital; Xinrui Capital; Broad Vision Funds; China-Singapore Suzhou; Yushi Space; Baidu Capital; Hillhouse CapitalLeadervc.com; Suzhou Angel Fund of Funds; China-Singapore Suzhou; DT Capital Partners; Honest Capital; Inovance; Oriza Holdings; Qianrong Venture Capital; Shanghai Electric Power Technology Fund; Oriza Seed Capital (Oriza Yuandian); Anxin InvestmentChina-Singapore Suzhou; Zhidao CapitalXianghe Capital; China-Singapore Suzhou; Eisai Co.; Sino-Singapore Capital; LC Ventures; SDIC Venture Capital
Valuationundisclosedundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all China-Singapore Suzhou investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About China-Singapore Suzhou

Who are competitors of China-Singapore Suzhou?China-Singapore Suzhou main competitors include GIMV, Kinnevik, Georgia Capital, Antin Infrastructure Partners, Rocket Internet, Molten Ventures, Bure Equity, China Everbright, Fairfax India Holdings, Ratos.

See public comps similar to China-Singapore Suzhou

Lists including China-Singapore Suzhou

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial